Article Text

PDF

A5.20 Intravenous Immunoglobulin Induces Functionnal Silencing in Human B Lymphocytes
  1. Sophie Hillion,
  2. Jean-François Seité,
  3. Carole Goutsmedt,
  4. Pierre Youinou,
  5. Jacques-Olivier Pers
  1. EA2216 Immunology & Pathology, Brest University and European University of Brittany, Brest, France

Abstract

Purpose/Objective Inappropriate B cell receptor (BCR) signalling contributes to the activation of auto-antibody-producing B cells in many autoimmune diseases. These diseases results from a break in B-cell tolerance which is normally maintained by the mechanisms of anergy, receptor editing and deletion. We previously showed that IVIg modulates many B cell responses through a sialic acid-CD22 lectin interaction (Séité, Blood 2010, Séité, J Autoimmunity, 2011). Here, we reasoned that IVIg could modulate B-cell fate and may render autoreactive B cells tolerant through induction of a functional unresponsiveness response to BCR stimulation.

Material and Methods Tonsilar B-cells were stimulated in the presence of different fractions of IVIg. We analysed subsequent responses to BCR stimulation by confocal microscopy, quantitative RT-PCR, FACS and Western-blot analysis.

Results First, we observed that up-regulation of costimulatory molecules CD86, CD80 and CD40 induced by BCR cross-linking was down-regulated after IVIg incubation and was associated with a massive reduction of tyrosine phosphorylation. Low mobilisation of intracellular Calcium, which is a hallmark of anergy, was also observed in IVIg-treated B cells. Next, we observed that following BCR stimulation, IVIg blocks BCR aggregation within lipid rafts and increases its internalisation. Consequently, BCR stimulation is not achievable and results in a low activation of the PI3K-Akt signalling pathway. Finally, we demonstrated that IVIg down-regulates NFκB activation and promotes NFAT transcription factors entry in the nucleus. These findings demonstrated that IVIg induces a selective transcriptional programme, allowing nuclear signals to be independently activated, leading to alternative B cell fates.

Conclusions Our data suggest that IVIg could induce B cells to adopt a state that results in a functional silencing, also called anergy. Our findings provide insights into the effectiveness of IVIg in treating pathologies associated with the loss of B cell tolerance. We also describe a new model to explore the complexity of positive versus negative selection in human B cells.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.